Immunotherapy and targeted therapy for advanced anal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with advanced anal cancer that has spread or come back. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a confirmed diagnosis of anal squamous cell cancer.
- Your cancer has spread to other parts of the body (stage 4) or cannot be removed with surgery.
- You have had at least one previous chemotherapy treatment, or you cannot receive chemotherapy.
- You are able to perform daily activities with some help (ECOG score 0, 1, or 2).
- You have adequate organ function, such as kidney, liver, and heart, and are willing to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, for people with anal or rectal cancer that has spread or cannot be removed and has worsened after initial treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This study tests a combination of new and existing drugs, followed by chemoradiotherapy with immunotherapy, for people with locally advanced squamous cell carcinoma of the anal canal. It aims to see if this approach is safe and effective.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
Hear when a new Anal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.